Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) and Half-Year (H1) ended 30 June 2026
Announcement Date: 28 July 2026
GSK reported strong core performance driven by Specialty Medicines and Vaccines, offset by significant impairments in Total results. The company announced an "Accelerate Growth" programme to fund R&D investments and a new flagship R&D Centre in Cambridge, UK.
Key Financial Metrics (Q2 2026)
| Metric | Q2 2026 Value | Q2 2025 Value | Growth (CER%) |
|---|---|---|---|
| Turnover | £8,409 million | £7,986 million | +5% |
| Total Operating Profit | £481 million | £2,023 million | -75% |
| Total EPS | 10.8p | 35.5p | -69% |
| Core Operating Profit | £2,800 million | £2,631 million | +7% |
| Core EPS | 50.5p | 46.5p | +9% |
| Cash from Operations | £2,906 million | £2,433 million | +19% |
| Free Cash Flow | £1,994 million | £1,126 million | +77% |
| Total Net Debt | £15,132 million | £13,735 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total sales grew 5% at constant exchange rates (CER). Specialty Medicines sales increased 14% (HIV +10%, Oncology +17%, RI&I +19%). Vaccines sales rose 8% (Arexvy +>100%, Meningitis +21%). General Medicines declined 9% (Trelegy -7%).
- Profitability Divergence: While Core Operating Profit grew 7%, Total Operating Profit fell 75% and Total EPS dropped 69%.
- Impairments: The decline in Total results was primarily driven by a £1.3 billion impairment of camlipixant (following negative Phase III results) and a £371 million impairment related to the termination of assets under the Alector collaboration.
- Other Adjusting Items: Higher Contingent Consideration Liability (CCL) charges and divestment income (linerixibat) impacted Total results.
- Acquisitions: GSK completed acquisitions of RAPT Therapeutics and 35Pharma in Q1/Q2 2026. A post-balance sheet acquisition of Nuvalent Inc. closed on 15 July 2026 for approximately $10.6 billion.
Guidance, Outlook, and Management Commentary
2026 Guidance (Reaffirmed at CER)
- Turnover: Increase of 3% to 5% (upper half of range).
- Core Operating Profit: Increase of 7% to 9% (upper half of range).
- Core EPS: Increase of 7% to 9% (lower half of range).
Strategic Initiatives
- Accelerate Growth Programme: A 3-year initiative targeting £1.9 billion in annual savings by 2029 to fund late-stage R&D and improve margins during the dolutegravir loss of exclusivity period (2028-2030).
- R&D Pipeline: Expectation of 20+ Phase III trial starts in 2026 (up from 10). Key assets include Jideytro (FDA approved), neladalkib (PDUFA H2 2026), and bepirovirsen (functional cure data positive).
- Shareholder Returns: Q2 dividend of 17p declared; full-year 2026 dividend expected at 70p. Completed a £2 billion share buyback programme in June 2026.
Risks and Contingencies
- Legal Matters: Ongoing Zantac litigation (summary judgment granted in Delaware, appeal filed); Avandia class certification vacated by Third Circuit; Zejula royalty dispute settled.
- Regulatory: Agreement with US Government to lower prescription costs and exclude GSK/ViiV from Section 232 tariffs through 2029.
- Geopolitical: Elevated risk regarding regulatory environment and trade policies.
Investor Verification Checklist
- Impairment Details: Verify the specific recoverable amount calculations for camlipixant and the impact of the Alector collaboration termination on future R&D spend.
- Nuvalent Acquisition: Review provisional accounting for the $10.6 billion Nuvalent acquisition (closed post-period) and its impact on Q3 2026 results and debt levels.
- Accelerate Growth Savings: Monitor the realization of the targeted £1.9 billion annual savings and the associated restructuring costs in 2026-2027.
- Contingent Consideration: Assess the sensitivity of the £6.78 billion contingent consideration liability to changes in sales forecasts and discount rates.
- General Medicines Decline: Evaluate the trajectory of Trelegy sales given US Medicare benefit design changes and pricing pressures.